CoChat

Plasma Total-Tau and Neurofilament Light Chain as Diagnostic Biomarkers of Alzheimer’s Disease Dementia and Mild Cognitive Impairment in Adults with Down Syndrome

Open access
Petersen, Melissa E., for the Alzheimer’s Biomarker Consortium –Down Syndrome (ABC-DS), Rafii, Michael S., Zhang, Fan, Hall, James, Julovich, David, Ances, Beau M., Schupf, Nicole, Krinsky-McHale, Sharon J., Mapstone, Mark, Silverman, Wayne, Lott, Ira, Klunk, William, Head, Elizabeth, Christian, Brad, Foroud, Tatiana, Lai, Florence, Diana Rosas, H., Zaman, Shahid, Wang, Mei-Cheng, Tycko, Benjamin, Lee, Joseph H., Handen, Benjamin, Hartley, Sigan, Fortea, Juan, O’Bryant, Sid · 2021 · Journal of Alzheimer's Disease
Cited by 48

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Background: The need for diagnostic biomarkers of cognitive decline is particularly important among aging adults with Down syndrome (DS). Growing empirical support has identified the utility of plasma derived biomarkers among neurotypical adults with mild cognitive impairment (MCI) and Alzheimer’s disease (AD); however, the application of such biomarkers has been limited among the DS population. Objective: This study aimed to investigate the cross-sectional diagnostic performance of plasma neurofilament light chain (Nf-L) and total-tau, individually and in combination among a cohort of DS adults. Methods: Plasma samples were analyzed from n = 305 (n = 225 cognitively stable (CS); n = 44 MCI-DS; n = 36 DS–AD) participants enrolled in the Alzheimer’s Biomarker Consortium —Down Syndrome. Results: In distinguishing DS-AD participants from CS, Nf-L alone produced an AUC of 90%, total-tau alone reached 74%, and combined reached an AUC of 86%. When age and gender were included, AUC increased to 93%. Higher values of Nf-L, total-tau, and age were all shown to be associated with increased risk for DS-AD. When distinguishing MCI-DS participants from CS, Nf-L alone produced an AUC of 65%, while total-tau alone reached 56%. A combined model with Nf-L, total-tau, age, and gender produced an AUC of 87%. Both higher values in age and total-tau were found to increase risk for MCI-DS; Nf-L levels were not associated with increased risk for MCI-DS. Conclusion: Advanced assay techniques make total-tau and particularly Nf-L useful biomarkers of both AD pathology and clinical status in DS and have the potential to serve as outcome measures in clinical trials for future disease-modifying drugs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3233/jad-201167

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 48

Metadata

Authors
Petersen, M. E., for the Alzheimer’s Biomarker Consortium –Down Syndrome (ABC-DS), Rafii, M. S., Zhang, F., Hall, J., Julovich, D., Ances, B. M., Schupf, N., Krinsky-McHale, S. J., Mapstone, M., Silverman, W., Lott, I., Klunk, W., Head, E., Christian, B., Foroud, T., Lai, F., Diana Rosas, H., Zaman, S., Wang, M.-C., Tycko, B., Lee, J. H., Handen, B., Hartley, S., Fortea, J., & O’Bryant, S.
Venue
Journal of Alzheimer's Disease
Published
2021-01-19
Volume
79
Issue
2
Pages
671-681
ISSN
  • 1387-2877 (ISSN-L)
  • 1875-8908
OpenAlex
W3111878236
Cited by
48
References
7
FWCI
3.51
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Plasma Total-Tau and Neurofilament Light Chain as Diagnostic Biomarkers of Alzheimer’s Disease Dementia and Mild Cognitive Impairment in Adults with Down Syndrome. https://app.cochat.ai/papers/10.3233/jad-201167
The paper
Petersen, M. E., for the Alzheimer’s Biomarker Consortium –Down Syndrome (ABC-DS), Rafii, M. S., Zhang, F., Hall, J., Julovich, D., Ances, B. M., Schupf, N., Krinsky-McHale, S. J., Mapstone, M., Silverman, W., Lott, I., Klunk, W., Head, E., Christian, B., Foroud, T., Lai, F., Diana Rosas, H., Zaman, S., . . . O’Bryant, S. (2021). Plasma Total-Tau and Neurofilament Light Chain as Diagnostic Biomarkers of Alzheimer’s Disease Dementia and Mild Cognitive Impairment in Adults with Down Syndrome. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-201167

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.